Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28751840
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Clinical pathways and management of antithrombotic therapy in patients with acute
coronary syndrome (ACS): a Consensus Document from the Italian Association of
Hospital Cardiologists (ANMCO), Italian Society of Cardiology (SIC), Italian
Society of Emergency Medicine (SIMEU) and Italian Society of Interventional
Cardiology (SICI-GISE)
#MMPMID28751840
De Luca L
; Colivicchi F
; Gulizia MM
; Pugliese FR
; Ruggieri MP
; Musumeci G
; Cibinel GA
; Romeo F
Eur Heart J Suppl
2017[May]; 19
(Suppl D
): D130-D150
PMID28751840
show ga
Antiplatelet therapy is the cornerstone of the pharmacologic management of
patients with acute coronary syndrome (ACS). Over the last years, several studies
have evaluated old and new oral or intravenous antiplatelet agents in ACS
patients. In particular, research was focused on assessing superiority of two
novel platelet ADP P2Y12 receptor antagonists (i.e., prasugrel and ticagrelor)
over clopidogrel. Several large randomized controlled trials have been undertaken
in this setting and a wide variety of prespecified and post-hoc analyses are
available that evaluated the potential benefits of novel antiplatelet therapies
in different subsets of patients with ACS. The aim of this document is to review
recent data on the use of current antiplatelet agents for in-hospital treatment
of ACS patients. In addition, in order to overcome increasing clinical challenges
and implement effective therapeutic interventions, this document identifies all
potential specific care pathway for ACS patients and accordingly proposes
individualized therapeutic options.
free
free
free
